Off-Label GLP-1s Are Redefining PCOS Care, But Long-Term Use and Access Remain Unclear
An increasing number of women with PCOS/PMOS are using off-label GLP-1 drugs like Ozempic to address insulin resistance and metabolic symptoms, with many reporting improved cycles and weight loss; some studies also show higher pregnancy rates when GLP-1s are added to metformin. Yet there is no FDA-approved PMOS indication, insurance coverage is inconsistent and costly, and long-term durability of benefit and optimal treatment duration remain under study; guidelines still emphasize lifestyle changes and metformin as first-line therapy, while patient experiences and online communities highlight a gap between care and what patients are seeking.
